Center for Drug Evaluation, NMPA
国家药品监督管理局药品审评中心
elsewhere's corpus does not cover the Center for Drug Evaluation, NMPA as a subject. The retrieved material mentions the National Medical Products Administration (NMPA) only in entity-card form without substantive description, and the document chunks are focused on drug R&D processes, biotech companies, and China's healthcare system rather than on this regulatory body itself.
AI-generated — may contain errors, please verify.
Coverage
Triastek Secures China's First 3D-Printed Drug Manufacturing License, Marking a New Era of Digital Innovation in Chinese Pharma | DaoTong Family
In September 2025, **Triastek, a Dalton Venture portfolio company, received the nation's first Pharmaceutical Manufacturing License for 3D-printed drug production issued by the Jiangsu Provincial Medical Products Administration**. This marks the first time that 3D printing pharmaceutical technology in China has achieved compliant, regulated manufacturing. It represents a critical step forward for Triastek in drug R&D and industrialization, as well as another milestone for Dalton Venture's investments in pharmaceutical innovation.
Interview with RayzeBio: Two Funding Rounds in Six Months, How the Surging "Radiopharma" Sector Is Transforming Cancer Treatment | Gaorong Ventures
Accelerating on the "fast track" of TRT therapy.
5Y News | AI Microbiome Drug Developer "Unknown" Closes Nearly $100 Million Series B Financing
Launching a new AI×BT strategy.
